trial

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

NCTId NCT03497299
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2022-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-07-01
Primary completion
2022-08-31
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Active rTMS (20Hz)

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
Yale UniversityCollaborator
Oregon State UniversityCollaborator

Sites

0 total

Linked catalysts

1
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia — primary completion2022-08-31

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2022-08-31
Status
WITHDRAWN
relationships
The graph out of here
drug
Active rTMS (20Hz)
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
Yale University
company
Oregon State University
company
indication
Smoking
indication
Tobacco Use Disorder
indication
Schizophrenia
indication